MARKETS / NASDAQ / IVF
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP

Invo Fertility, Inc. IVF

15 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$6.8M
▲ 4.7% vs FY2024
EPS · FY25
$-214.64
Dividend / sh · FY25
Payout · FY25
ROE · FY25
-235.5%
Net margin · FY25
-340.9%
Dividend coverage
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 6.8M
Revenue, FY2025 · full 15-year series below
Revenue Net income
0.0020.0040.0060.0080.0-0.0201120142017202020232025
0.0020.0040.0060.0080.0-0.02016201920222025

The company lost 341 cents on every revenue dollar this year.

Per share
USD -214.64
Diluted EPS, FY2025
EPS
0.40.81.2-214.64201120142017202020232025
0.40.81.2-214.642016201920222025

The company pays no cash dividend.

Profitability
-235.5%
Return on equity, FY2025
ROE
0.250.50.751-235.5%201120142017202020232025
0.250.50.751-235.5%2016201920222025
Operating margin-105.8%
Net margin-340.9%
Return on assets-70.4%

Each USD of equity lost 235 cents this year.

Returned to shareholders
returned in FY2025 · dividends + net buybacks
Dividends paid
Net buybacks
Share of profit
Consecutive raises

Growth
+45.8% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+102.6%
+45.8%
+89.1%

Compound annual rates per period — left blank where the series crosses a loss.

Share base
0.00B
Shares outstanding, FY2025
0.080.00201120142017202020232025
0.140.002016201920222025
Change, 5 years+38.5%
Change, 10 years

The share count grew 39% in five years — the same company, cut into more, smaller slices.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 20.2M
total assets, end of FY2025
Total assetsUSD 20.2M
EquityUSD 7.2M
Gross debtUSD 2.0M
Current ratio0.27×

Equity funds 36% of total assets.

History
15 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−214.64
−3782.65
−67.37
−17.97
−0.63
−1.52
−0.45
−0.02
0.00
−0.02
−0.04
−0.02
−0.01
−0.01
−0.01
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−235.5
−137.4
·
−344.0
−102.0
−822.6
·
·
·
·
·
·
·
·
·
Shares out B
0.00
0.00
0.00
0.00
0.01
0.01
0.00
0.15
0.14
0.14
0.14
0.12
0.11
0.09
0.08

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
56 of 56
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed